Background: Prostate cancer is the second most common cancer among males worldwide. The prostate cancer diagnostic pathway offers transrectal ultrasound-guided biopsy (TRUS-biopsy) in men who present with an elevated serum prostate specific antigen (PSA). As a result, many men without cancer undergo unnecessary biopsies, clinically insignificant cancers are often detected, & clinically significant cancers are sometimes missed. TRUS-biopsy also carries significant morbidity and can cause life threatening sepsis.